Dr. Kennedy on the Utilization of Radioactive Microspheres

Video

In Partnership With:

Andrew Kennedy, MD, physician-in-chief, Radiation Oncology, Sarah Cannon, director, Radiation Oncology Research, Sarah Cannon Research Institute, discusses the utilization of radioactive microspheres.

Andrew Kennedy, MD, physician-in-chief, Radiation Oncology, Sarah Cannon, director, Radiation Oncology Research, Sarah Cannon Research Institute, discusses the utilization of radioactive microspheres.

Kennedy says the radioactive microspheres can only be used to treat tumors in the liver that cannot be removed by surgery. If the patient’s tumor is not responding or even partially responding to chemotherapy, they should be considered for radioactive microsphere treatment.

Surgery is the only curative approach for tumors in the liver, Kennedy says. If the tumors cannot be removed, using radioactive microspheres usually dramatically controls the tumors in the liver for months to years, but can sometimes kill the tumor completely.

Kennedy says this allows patients to still receive chemotherapy while getting better control of the tumors in the liver.

Related Videos
Video 10 - "Monitoring and AE Management Strategies with Fruquintinib in CRC"
Video 9 - "FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC"
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles